CN109496217B - 具有cd3结合域的基于多聚体il-15的分子的构造和表征 - Google Patents

具有cd3结合域的基于多聚体il-15的分子的构造和表征 Download PDF

Info

Publication number
CN109496217B
CN109496217B CN201780045989.XA CN201780045989A CN109496217B CN 109496217 B CN109496217 B CN 109496217B CN 201780045989 A CN201780045989 A CN 201780045989A CN 109496217 B CN109496217 B CN 109496217B
Authority
CN
China
Prior art keywords
cells
fusion protein
domain
cell
2b8t2m
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780045989.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN109496217A (zh
Inventor
刘白
彼得·罗德
黄兴忠
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Altor Bioscience LLC
Original Assignee
Altor Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altor Bioscience LLC filed Critical Altor Bioscience LLC
Priority to CN202311304218.1A priority Critical patent/CN117362450A/zh
Publication of CN109496217A publication Critical patent/CN109496217A/zh
Application granted granted Critical
Publication of CN109496217B publication Critical patent/CN109496217B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201780045989.XA 2016-05-27 2017-05-26 具有cd3结合域的基于多聚体il-15的分子的构造和表征 Active CN109496217B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311304218.1A CN117362450A (zh) 2016-05-27 2017-05-26 具有cd3结合域的基于多聚体il-15的分子的构造和表征

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662342311P 2016-05-27 2016-05-27
US62/342,311 2016-05-27
US201662397236P 2016-09-20 2016-09-20
US62/397,236 2016-09-20
PCT/US2017/034656 WO2017205726A1 (en) 2016-05-27 2017-05-26 Construction and characterization of multimeric il-15-based molecules with cd3 binding domains

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311304218.1A Division CN117362450A (zh) 2016-05-27 2017-05-26 具有cd3结合域的基于多聚体il-15的分子的构造和表征

Publications (2)

Publication Number Publication Date
CN109496217A CN109496217A (zh) 2019-03-19
CN109496217B true CN109496217B (zh) 2023-10-20

Family

ID=60412970

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780045989.XA Active CN109496217B (zh) 2016-05-27 2017-05-26 具有cd3结合域的基于多聚体il-15的分子的构造和表征
CN202311304218.1A Pending CN117362450A (zh) 2016-05-27 2017-05-26 具有cd3结合域的基于多聚体il-15的分子的构造和表征

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311304218.1A Pending CN117362450A (zh) 2016-05-27 2017-05-26 具有cd3结合域的基于多聚体il-15的分子的构造和表征

Country Status (7)

Country Link
US (1) US10865230B2 (https=)
EP (1) EP3464352B1 (https=)
JP (1) JP7037506B2 (https=)
KR (2) KR102463844B1 (https=)
CN (2) CN109496217B (https=)
AU (1) AU2017271593B2 (https=)
WO (1) WO2017205726A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2160401T3 (da) 2007-05-11 2014-10-20 Altor Bioscience Corp Fusionsmolekyler og il-15-varianter
CN107880136B (zh) 2010-09-21 2021-11-12 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
SI3094351T1 (sl) * 2014-01-15 2022-05-31 Kadmon Corporation, Llc Imunomodulatorna sredstva
CA3151221C (en) 2014-06-30 2026-01-13 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
AU2017271593B2 (en) 2016-05-27 2021-04-22 Altor Bioscience Corporation Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
JP7185530B2 (ja) 2016-06-13 2022-12-07 トルク セラピューティクス， インコーポレイテッド 免疫細胞機能を促進するための方法および組成物
CN118562016A (zh) 2016-10-21 2024-08-30 艾尔特生物科技公司 基于多聚体il-15的分子
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
AU2018385699B2 (en) * 2017-12-14 2024-08-15 Regeneron Pharmaceuticals, Inc. Daric interleukin receptors
TW201938196A (zh) * 2018-01-18 2019-10-01 美商南特生物科學股份有限公司 融合蛋白擴展
JP2021514625A (ja) * 2018-03-01 2021-06-17 グリコトープ ゲーエムベーハー 抗ｍｕｃ１抗体およびｉｌ−１５を含む融合タンパク質構築物
TW202003011A (zh) 2018-03-26 2020-01-16 美商艾爾特生物科技責任有限公司 抗ＰＤＬ１、ＩＬ－１５及ＴＧＦ－β受體組合分子
US11267866B2 (en) 2018-04-04 2022-03-08 Nant Holdings Ip, Llc Immunoglobulin complex comprising interleukin-15
WO2020037120A1 (en) 2018-08-16 2020-02-20 Nantbio, Inc. Il7-il15 txm compositions and methods
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
WO2021041886A1 (en) * 2019-08-29 2021-03-04 Nantbio, Inc. Modified n-810 and methods therefor
US20230097573A1 (en) * 2019-10-16 2023-03-30 Lg Chem, Ltd. Neonatal fc receptor binding affimers
CN111690069B (zh) * 2019-11-13 2022-04-19 中国科学技术大学 一种IL-15/SuIL-15Rα-mFc-γ4复合体蛋白及其构造方法、应用
CN113135996A (zh) * 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
CN114106195B (zh) * 2020-08-27 2024-09-17 盛禾(中国)生物制药有限公司 一种多功能融合蛋白及其用途
WO2022042576A1 (zh) * 2020-08-27 2022-03-03 盛禾(中国)生物制药有限公司 一种多功能融合蛋白及其用途
US20230405122A1 (en) * 2020-11-24 2023-12-21 City Of Hope Compositions and uses of psca targeted chimeric antigen receptor modified cells
CN112795543B (zh) * 2021-02-04 2022-09-27 华中农业大学 杂交瘤细胞株及其分泌的抗草鱼IL-15Rα单克隆抗体和应用
BR112023021886A8 (pt) * 2021-04-22 2024-01-09 Guangdong Fapon Biopharma Inc Polipeptídeo de fusão biespecífico multifuncional
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
JP7734994B2 (ja) * 2021-06-02 2025-09-08 クレ バイオテクノロジ （シャンハイ） カンパニー リミテッド 抗ｃｄ３抗体変異体、融合タンパク質および適用
WO2023006082A1 (zh) * 2021-07-30 2023-02-02 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
CN116143942A (zh) * 2021-09-09 2023-05-23 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
CN115806628A (zh) * 2022-08-03 2023-03-17 深圳市先康达生命科学有限公司 一种自分泌IL-15与anti-TIGIT结合的融合蛋白及其应用
WO2024197709A1 (zh) * 2023-03-30 2024-10-03 中国科学院深圳先进技术研究院 一种t细胞衔接器及其制备方法和应用
AU2024269870A1 (en) * 2023-05-05 2025-11-20 Board Of Regents, The University Of Texas System Multi-receptor natural killer cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143794A1 (en) * 2007-05-11 2008-11-27 Altor Bioscience Corporation Fusion molecules and il-15 variants
CN101842117A (zh) * 2007-08-28 2010-09-22 比奥根艾迪克Ma公司 抗igf-1r抗体及其用途
WO2016018920A1 (en) * 2014-07-29 2016-02-04 Admune Therapeutics Llc Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
CN105531374A (zh) * 2013-07-12 2016-04-27 酵活有限公司 双特异性cd3和cd19抗原结合构建体

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
WO1994004689A1 (en) 1992-08-14 1994-03-03 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Recombinant toxin with increased half-life
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5534592A (en) 1995-09-22 1996-07-09 The Goodyear Tire & Rubber Company High performance blend for tire treads
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US8772451B2 (en) 2003-11-10 2014-07-08 Altor Bioscience Corporation Soluble TCR molecules and methods of use
EP1586585A1 (de) * 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung
CN107880136B (zh) 2010-09-21 2021-11-12 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CA3151221C (en) 2014-06-30 2026-01-13 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
KR20180125435A (ko) 2015-09-25 2018-11-23 알토 바이오사이언스 코포레이션 이식편 대 종양 활성을 현저하게 향상시키는 인터루킨-15 수퍼아고니스트
AU2017271593B2 (en) 2016-05-27 2021-04-22 Altor Bioscience Corporation Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
US20190048055A1 (en) 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143794A1 (en) * 2007-05-11 2008-11-27 Altor Bioscience Corporation Fusion molecules and il-15 variants
CN101842117A (zh) * 2007-08-28 2010-09-22 比奥根艾迪克Ma公司 抗igf-1r抗体及其用途
CN105531374A (zh) * 2013-07-12 2016-04-27 酵活有限公司 双特异性cd3和cd19抗原结合构建体
WO2016018920A1 (en) * 2014-07-29 2016-02-04 Admune Therapeutics Llc Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
L-15: IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization;Han K et al.;《Cytokine》;20111022;第56卷(第3期);全文 *

Also Published As

Publication number Publication date
EP3464352A4 (en) 2019-10-23
KR102463844B1 (ko) 2022-11-08
US20170342119A1 (en) 2017-11-30
EP3464352A1 (en) 2019-04-10
KR20190016979A (ko) 2019-02-19
AU2017271593A1 (en) 2018-12-13
CN117362450A (zh) 2024-01-09
JP2019519227A (ja) 2019-07-11
WO2017205726A1 (en) 2017-11-30
US10865230B2 (en) 2020-12-15
JP7037506B2 (ja) 2022-03-16
CA3025343A1 (en) 2017-11-30
CN109496217A (zh) 2019-03-19
AU2017271593B2 (en) 2021-04-22
KR20220148306A (ko) 2022-11-04
EP3464352B1 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
CN109496217B (zh) 具有cd3结合域的基于多聚体il-15的分子的构造和表征
JP7561905B2 (ja) Ｉｌ－１５ベース分子及びその使用方法
CN111867612B (zh) 抗PDL1、IL-15和TGF-β受体组合分子
CN111655716B (zh) 基于il-15的与il-7和il-21的融合体
CN110785435B (zh) 与il-12和il-18的基于il-15的融合物
JP7492336B2 (ja) 多量体ｉｌ－１５に基づく分子
CA3025343C (en) Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
HK40007105B (en) Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
HK40007105A (en) Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
HK40014316A (en) Multimeric il-15-based molecules
HK40014316B (en) Multimeric il-15-based molecules

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant